European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-1 Inhibitors
U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
Gilead's Livdelzi® Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1-1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi
FDA Grants Accelerated Approval to Gilead's Hepcludex® , the First and Only Approved Treatment for Chronic Hepatitis Delta Virus
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-1 Inhibitors
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
QIMC Reports Multiple Elevated Hydrogen Mud-Gas Readings Over 100m-250m Interval of DDH-26-04, Including a Peak Hydrogen Reading of 16.0%, Two Hydrogen Readings of 13.5%, and Nine Readings at or Above 5% Hydrogen
Oreterra Completes Airborne Geophysical Survey of the Kinkaid Cu-Au-Ag Project, Nevada, Identifies Significant New Porphyry Target
